Stockreport

RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results On November 6, 2025, RBC Capital raised its price target on Viridian Therapeutic [Read more]